| Literature DB >> 22229212 |
Abstract
Sarcoma metastasizes to the lungs in 20% to 40% of patients and in most cases does not involve any other organ. Systemic chemotherapy is of unproven benefit for stage IV sarcoma. Retrospective studies have shown 5-year survival rates of 21% to 38% with wedge resection of metastatic pulmonary nodules, and up to 30% to 40% of patients survive an additional 5 years with repeated metastasectomy. In this article, we provide an extensive review of patient selection criteria and surgical approaches, as well as of controversies regarding resection for metastatic sarcoma.Entities:
Mesh:
Year: 2011 PMID: 22229212
Source DB: PubMed Journal: Oncology (Williston Park) ISSN: 0890-9091 Impact factor: 2.990